Fieldpoint Private Securities’s Neurocrine Biosciences NBIX Stock Holding History

Fieldpoint Private Securities’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$102K	Sell	1,046 -42	-4%	-$3.88K	0.03%	363
2022 Q1	$102K	Buy	1,088 +55	+5%	+$4.66K	0.02%	434
2021 Q4	$88K	Sell	1,033 -20	-2%	-$1.84K	0.02%	466
2021 Q3	$101K	Hold	1,053	–	–	0.02%	413
2021 Q2	$92K	Buy	1,053 +17	+2%	+$1.63K	0.02%	436
2021 Q1	$101K	Sell	1,036 -301	-23%	-$31.6K	0.02%	402
2020 Q4	$128K	Buy	+1,337	New	+$129K	0.03%	359

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Fieldpoint Private Securities's NBIX Position: Q2 2022 in Review

Fieldpoint Private Securities reduced its Neurocrine Biosciences (NBIX) stake by 3.9% in Q2 2022, selling an estimated $3.88K and leaving 1,046 shares worth $102K. The position accounts for 0.03% of the portfolio, ranked #363.

Fieldpoint Private Securities first reported a position in NBIX in Q4 2020 and has held it in 7 quarters since. The position peaked at $128K in Q4 2020. 438 funds tracked by Wall St. Rank hold NBIX as of Q2 2022.

Fieldpoint Private Securities held 1,046 shares of Neurocrine Biosciences worth $102K as of Q2 2022.
Fieldpoint Private Securities sold 42 Neurocrine Biosciences shares in Q2 2022, an estimated $3.88K.
Neurocrine Biosciences made up 0.03% of Fieldpoint Private Securities's portfolio in Q2 2022, its #363 holding.
Fieldpoint Private Securities first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 7 quarters since.
Fieldpoint Private Securities's Neurocrine Biosciences position peaked at $128K in Q4 2020.
438 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.